Galapagos N.V. GLPG
27.98 USD 0.00 (+0.00%)
Jun 4, 2026, 11:58 AM EDT
27.50 Day range 28.09
52-week range unavailable
- YTD
- -14.43%
- 1 year
- -3.08%
- Market cap
- 1.84B
- Profit margin
- 46.83%
- YTD return
- -14.43%
- 1-year return
- -3.08%
- Volume
- 2.38K
- Open
- 27.50
- Previous close
- 27.98
- Day's range
- 27.50 – 28.09
- Earnings date
- Aug 10, 2026
2Y +1.28 (+4.79%)
Key statistics
- Enterprise value
- 1.81B
- PEG ratio
- -0.10
- Price / sales
- 0.00
- Price / book
- 0.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 16.88%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 10, 2026
Expected Aug 10, 2026. Consensus EPS estimate 0.00.
Financials — quick view
GLPG Revenue — quarterly 8.06M
GLPG Net income — quarterly 14.49M
GLPG EPS — quarterly 0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2026 | Jun 30, 2026 | -0.96723 | — | — | — |
| May 6, 2026 | Mar 31, 2026 | -1.27 | 0.25 | +1.52 | +119.69% |
| Feb 23, 2026 | Dec 31, 2025 | 1.00 | 16.38 | +15.38 | +1,538.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.20 | -3.59 | -3.39 | -1,696.35% |
| Jul 23, 2025 | Jun 30, 2025 | -0.67 | -1.89 | -1.22 | -182.27% |
| Apr 23, 2025 | Mar 31, 2025 | -0.23 | -2.47 | -2.24 | -973.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 7, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 22, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 21, 2025 | Leerink Partners | up | Market Perform | Outperform |
| Feb 14, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jan 23, 2025 | Barclays | down | Equal-Weight | Underweight |
About Galapagos N.V.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- BE
- Employees
- 452
- Website
- lakefrontbio.com
News
Earnings Scheduled For May 6, 2026 - Earnings Scheduled For February 23, 2026
12 Health Care Stocks Moving In Monday's After-Market Session 
Earnings Scheduled For November 5, 2025 
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
Earnings Scheduled For July 23, 2025 
Earnings Scheduled For April 23, 2025
Your note
Sign in to keep a note on GLPG — it syncs with the Stock Master app.